The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
May 23, 2016
View Complete Issue         Table of Contents 2019 
Three New Drugs for Multiple Myeloma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Three New Drugs for Multiple Myeloma (online only)
May 23, 2016 (Issue: 1495)
The FDA recently approved ixazomib (Ninlaro – Takeda), daratumumab (Darzalex – Janssen Biotech), and elotuzumab (Empliciti – BMS) for treatment of relapsed and/or refractory multiple myeloma.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Three New Drugs for Multiple Myeloma (online only)
Article code: 1495d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.